Search is Powered by Google
Cancer / Oncology News

$10.9M NCI Grant For Studies Of Virus Cancer Models

Main Category: Cancer / Oncology
Also Included In: Lymphoma / Leukemia;  Infectious Diseases / Bacteria / Viruses;  HIV / AIDS
Article Date: 19 Jul 2008 - 10:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

A team of researchers from Ohio State University's Comprehensive Cancer Center (OSUCCC) and the University's College of Veterinary Medicine have received a $10.9 million, five-year grant from the National Cancer Institute (NCI) to further their studies of retrovirus-associated cancer.

Principal investigator Michael Lairmore, DVM, PhD, professor and chair of the Department of Veterinary Biosciences, associate director for basic research at the OSUCCC, and a member of the OSUCCC's Viral Oncogenesis Program, leads the team.

The new grant follows a previous five-year, $8.9 million NCI grant received in 2003 for studies investigating how some retroviruses cause white blood cells, called lymphocytes, to proliferate, leading to cancer. Retroviruses include the human T-lymphotropic virus type I and II (HTLV-1 and HTLV-2), which have been linked to adult T-cell leukemia and lymphoma, and the human immunodeficiency virus (HIV), the cause of AIDS.

The study comprises five interactive projects with interrelated goals to define critical biological events that control the alteration of lymphocytes. "These findings will help us further discover therapeutic targets against retroviral-induced lymphoma and its lethal side effects syndromes, such as hypercalcemia," Lairmore says.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Source: Darrell E. Ward
Ohio State University Medical Center




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating Prostate Cancer Symptoms image Treating Prostate Cancer Symptoms

Many men will have advanced prostate cancer without any noticeable symptoms. Treatment for these patients is a bit different than for other patients with prostate cancer. Learn about these differences...

View more videos...